Articles tagged with Tuberculosis
India's TB epidemic is worsened by the failure of its Revised National Tuberculosis Control Program to engage the private sector, argues Dr. Zarir Udwadia. The program needs to provide free diagnosis and treatment to all patients, regardless of sector, to control the spread of TB.
The International Journal of Infectious Diseases publishes a special issue to mark World TB Day, highlighting recent successes and future challenges in eliminating TB. The issue presents new vaccine candidates, diagnostic techniques, and treatment options for drug-resistant strains.
A new TB drug regimen, PaMZ, has shown promising results in a Phase 2b clinical trial, demonstrating the potential to treat both drug-sensitive and multidrug-resistant TB in four to six months. The regimen, comprising pretomanid and moxifloxacin, was found to be effective independent of HIV status.
A large-scale genetic study of tuberculosis susceptibility has identified a key gene, ASAP1, that affects an individual's ability to fight the infection. The research found that variants of this gene impact susceptibility to TB and may hold clues to designing more effective vaccines for prevention.
The American College of Physicians recommends against routine cardiac screening for low-risk adults, citing insufficient evidence and potential harms. Instead, physicians should focus on mitigating cardiovascular risk through treating modifiable factors like smoking and hypertension.
Researchers at the University of Washington have developed a new approach to diagnosing tuberculosis (TB) using oral swab samples, greatly improving on standard diagnostics. The method was tested in 20 healthy individuals and 20 TB patients, detecting TB in 18 out of 20 confirmed cases.
Johns Hopkins researchers have identified a crucial molecular mechanism underlying the immune response to tuberculosis. By adjusting the levels of a specific molecule called c-di-AMP, they may be able to develop more effective human therapies for TB treatment.
Researchers at UGA have discovered a new small molecule drug that may serve as a treatment against multi-drug resistant tuberculosis. The compound works by interrupting the production of RNA, rendering the bacterium incapable of reproducing and spreading infection.
The National Institute of Allergy and Infectious Diseases (NIAID) is expanding its Tuberculosis Research Units (TBRU) program to improve understanding of TB latency and persistence. Four new institutions will collaborate on research projects focusing on biomarkers, metabolic factors and T cell responses to control TB.
The National Institutes of Health has awarded a $6.2 million grant to Weill Cornell Medical College to tackle the global tuberculosis epidemic. The grant, worth up to $45.7 million over seven years, aims to develop new treatments and shorten therapy duration for patients with drug-resistant TB.
Researchers identified key immune biomarkers that can help distinguish between HIV patients who experience life-threatening complications and those who fare well on treatment. The findings suggest that personalized approaches may be necessary for these patients, as a one-size-fits-all approach could worsen outcomes.
Researchers found that anti-TB granulomas have abnormal blood vessel networks, similar to solid tumors, which limit drug penetration. Treating these vessels with bevacizumab improved drug delivery and reduced oxygen-starved cells.
Regular cattle testing could lead to TB eradication regardless of badger culling, study suggests. Cattle housed in large sheds over winter can double infected animals in a herd.
A randomized clinical trial compared the safety and effectiveness of combination therapy with rifapentine and isoniazid to treatment only with isoniazid. The study found that combination therapy was as effective in preventing TB in children, with zero cases reported in the combination group compared to three in the isoniazid-only group.
A new multiple-target, real-time reverse transcription-PCR (real-time RT-PCR) TaqMan assay can differentiate between patients with latent TB and those with active disease. The assay targets eight human immune markers and has a sensitivity of up to 100% for active disease.
Researchers at Johns Hopkins Medicine have developed a new treatment strategy that allows lower doses of the toxic tuberculosis drug bedaquiline to retain potency while reducing side effects. This approach, which combines bedaquiline with verapamil, has shown promising results in mouse studies and is poised for clinical trials.
Scientists have discovered that Metformin can boost the efficacy of TB medication and stop Mtb replication without promoting drug resistance. This discovery could lead to a new and affordable treatment strategy for tuberculosis, potentially shortening clinical trials.
A Rutgers researcher has received a $640,000 NIH grant to develop a rapid Ebola test that can be used in remote locations where the disease has spread. The test, modeled after an existing tuberculosis test, will diagnose patients quickly and accurately, reducing the need for isolation and treatment delays.
Researchers used positron emission tomography (PET) and computed tomography (CT) imaging to monitor antibiotic treatment effects in TB-infected monkeys and humans. Changes in PET/CT scans over time accurately predicted treatment outcomes, potentially shortening clinical trials and saving resources.
A new study using PET scans reveals that these tests can accurately predict which TB treatment drugs are likely to be effective in human trials. The findings could lead to the development of more effective treatments for patients with multi-drug resistant TB.
Researchers found that blocking angiogenesis can reduce bacterial numbers, limit their spread and increase survival rates in infected lab animals. The study suggests a potential new therapeutic approach targeting the body's response to tuberculosis rather than directly attacking the bacteria.
A systematic review found that reminder systems, including pre-appointment prompts and contact with missed appointments, can significantly improve treatment completion rates. The review's findings suggest these policies have important benefits and can contribute to improving TB treatment outcomes.
Smoking increases susceptibility to TB infection, with white blood cells in smokers' lungs showing a weakened response to the disease. The discovery provides new insights into treating and preventing TB, which kills 1.5 million people annually.
Researchers at Boston University will identify biomarkers for TB infection and disease progression, aiming to reduce mortality rates. The study aims to develop new tools for preventing and treating TB, a deadly disease affecting millions globally.
REACH ETHIOPIA, a collaboration between LSTM, has been awarded the 2014 Kochon Prize for its innovative community-based TB treatment approach. The project doubled TB case notification in a 3-million population and achieved a treatment success rate of 93%, demonstrating the effectiveness of bringing services closer to communities.
A clinical trial in Sub-Sahara African countries shows a four-month TB treatment is well-tolerated and works for subsets of patients, but is not an alternative to the standard six-month treatment. The new regimen was beneficial for patients without lung cavitation, undernourished individuals, and those living with HIV.
EPFL scientists have developed two small molecules that can overcome the multidrug resistance of Mtb, a bacterium that causes tuberculosis. The compounds inhibit the secretion of virulence protein EsxA and exert multiple effects against Mtb's molecular apparatus.
A new study suggests that vaccines developed for adolescents and adults could have a significant impact on tuberculosis (TB) worldwide. The researchers found that these vaccines could provide dramatic levels of control needed to eliminate TB by 2050. However, the current BCG vaccine given to infants is not enough to achieve this goal.
Researchers at Ohio State University found that ibuprofen can reduce lung inflammation in elderly mice, improving their immune response to tuberculosis. By lowering inflammation, ibuprofen made the lungs of old mice appear younger and more effective at fighting infection.
Scientists from Brown University and MIT have discovered new details on how ADEPs bind to the ClpP complex in Mtb, a crucial step towards optimizing these compounds for TB treatment. Novel ADEP analogs show improved binding and activation of ClpP, paving the way for designing new drugs.
Experts at LSTM used a novel modelling approach to project the effects of new diagnostic methods and algorithms for TB in Tanzania. The integrated model compared the costs and effectiveness of different diagnostic options, identifying Xpert MTB/RIF as a cost-effective option with the potential to reduce the national burden of TB.
Researchers have developed a new DNA sequencing method that can detect and characterize the bacteria causing tuberculosis in a matter of days, without the need for time-consuming laboratory culture. The technique, known as metagenomics, uses high-throughput sequencing technologies to analyze DNA extracted from sputum samples.
Grand Challenges Canada awards $2.4 million to 22 projects addressing major health burdens in low-resource countries, including tuberculosis, deafness, and mental health problems. Innovations include a personal eyepiece for deaf children and sterile drill covers for low-cost orthopaedic trauma surgery.
A new series published in The Lancet Diabetes & Endocrinology finds that the growing global diabetes epidemic is hampering progress in controlling and eliminating tuberculosis. With over 1 million cases annually, diabetes-associated TB cases are expected to offset the present downward trend in global TB cases by 8% or more by 2035.
Researchers found that macrophages from the lungs of old mice had different responses to infections than those of young mice, but these changes were reversed by ibuprofen. The study suggests that reducing inflammation with diet, exercise, and/or drugs may help prevent or reduce diseases in the elderly.
Researchers have devised a genetic barcode that can identify different types of tuberculosis (TB) bacteria, allowing doctors to track the spread of the disease more effectively. The study found that just 62 mutations are needed to code the global family of strains, making it easier for scientists to map how TB moves around the world.
A new blood test provides a fast and accurate tool to diagnose tuberculosis in children, with excellent specificity and similar sensitivity as culture tests. The test features sputum-independent results available within 24 hours after blood sampling, making it a major advance for the diagnosis of tuberculosis in children.
Scientists found that ancient strains of tuberculosis were most closely related to those in seals and sea lions, suggesting the disease was transmitted from Africa to the Americas via marine animals. This discovery provides new insights into the origins of the disease and its spread among human populations.
Scientists have identified Mycobacterium pinnipedii in Peru skeletons dating back at least 1000 years, revealing seals as a source of pre-Columbian tuberculosis. This finding sheds new light on the history of the disease in the Americas and has implications for future vaccine development.
A UCLA-led study discovered a protein called interleukin-32 that helps protect people with latent tuberculosis from developing the active form of the disease. The researchers found that vitamin D levels play a crucial role in this protection, and supplementing with vitamin D may help prevent TB.
Researchers found evidence that Mycobacterial tuberculosis genomes in Peru's human skeletons match animal lineages from seals and sea lions. This suggests marine mammals brought the disease to South America before European arrival. The study provides strong evidence for a complex history of tuberculosis transmission in the Americas.
A new vaccine, rBCG30, offers superior protection against tuberculosis in animal models and cross-protection against leprosy. Boosting rBCG30 with the Antigen 85B protein significantly enhances its effectiveness against leprosy.
Scientists at Johns Hopkins Bloomberg School of Public Health have discovered a new clue to understanding how the most important medication for tuberculosis works. The antibiotic Pyrazinamide cuts off the energy production of Mycobacterium tuberculosis, killing the bacteria by disrupting PanD, an enzyme crucial to synthesis of co-enzym...
A commentary published in Annals of Internal Medicine reveals the history of 'miraculous' Ebola virus serotherapy, inspired by 19th century discoveries. Additionally, two systematic reviews address challenges of interpreting troponin levels in patients with chronic kidney disease.
The BCG vaccine has a 60-80% protective efficacy against severe forms of tuberculosis in children. Research found that the vaccine is effective against TB infection, with a 19% effectiveness rate among vaccinated children after exposure.
Researchers at the University of Bristol have developed a new strategy for disconnecting molecules, which could be used to create a tuberculosis (TB) vaccine. The method, described in Nature Chemistry, enables the synthesis of complex lipids like hydroxyphthioceranic acid in just 14 steps.
The study shows accelerated progress in reducing the global burden of HIV, malaria, and tuberculosis (TB) since governments adopted MDG 6. The number of people living with HIV has risen to around 29 million, while TB prevalence rates have decreased in many regions.
Researchers at the University of Otago have discovered a key mechanism that enables mycobacteria to survive in extreme conditions, using hydrogen as a high-energy fuel. By understanding this metabolic process, scientists hope to develop new antibiotics to tackle latent tuberculosis infections.
The number of deaths from HIV/AIDS, tuberculosis, and malaria has decreased significantly worldwide since 2000. In sub-Saharan Africa, child deaths from malaria have dropped by 31.5% in the past decade. Researchers attribute the decline to improved access to antiretroviral therapy and treatment.
A new mathematical model suggests that implementing Xpert MTB/RIF as part of a more ambitious rollout strategy, including private sector engagement and referral networks, could reduce TB incidence by 14.1% in India. The current narrow implementation strategy is expected to only reduce incidence by 0.2%.
A study by University of Illinois researchers found that TB-infected elephants have different immune responses to the infection compared to those without it. The team developed a new method to detect cytokine mRNA in elephants, which could lead to faster and more accurate diagnosis of tuberculosis in captive elephants.
A new study suggests that getting patients in India quickly evaluated by the right doctors can be as effective at curbing tuberculosis as a highly accurate screening test. Improving access to Xpert MTB/RIF, a new TB test, could reduce new cases by 14.1 percent over 5 years.
Research into bedaquiline, a new drug for multidrug-resistant tuberculosis (MDR-TB), should proceed cautiously in people with drug-sensitive tuberculosis. The drug has shown promising activity against MDR-TB but also presents safety concerns, including increased risk of liver and cardiac toxicity.
New estimates suggest that over 650,000 children develop TB annually in high-burden countries, with India accounting for 27% of the total burden. The study highlights an enormous opportunity for preventive antibiotic treatment among exposed children to reduce the number of cases.
A new TB test uses a fluorescent substrate to detect the BlaC enzyme in sputum samples, enabling fast and accurate diagnosis. The device is portable, easy to use, and undercuts current methods, with a target price tag of less than $1000.
Researchers found that a host genetic factor exacerbates lung damage in severe TB and suggests why gene mutations rendering it inactive are common. The study also showed that drugs targeting P2X7R could be used to treat aggressive forms of TB.
Researchers at ETH Zurich have developed a new approach for tuberculosis drugs, inspired by the bacteria-derived antibiotic pyridomycin. The new molecule is more stable and easier to produce synthetically, offering a potential solution to multidrug-resistant strains.
Scientists expect progress in developing an effective TB vaccine, with Phase IIa clinical trials underway. The new vaccine aims to activate both killer and helper cells for improved immune response.
Researchers at Oregon State University have successfully developed a new compound with improved antibacterial activity against multi-drug resistant strains of tuberculosis. The findings offer an important new avenue for treatment of the disease, which is responsible for over 1 million deaths annually.
Researchers found that people taking corticosteroid pills are at increased risk of developing active TB, but were less likely to be screened for the infection. Current guidelines may need to be revised to account for this increased risk and ensure timely screening.